Status:
UNKNOWN
Clinical Application of Methylene Blue for Treatment of Covid-19 Patients
Lead Sponsor:
Mashhad University of Medical Sciences
Conditions:
Covid-19
Eligibility:
All Genders
18-90 years
Phase:
PHASE1
Brief Summary
The severe acute respiratory syndrome caused by COVID-19 is now a global catastrophic event. Currently there is no approved drug or vaccine for the disease. Methylene blue (MB, oxidized form, blue col...
Eligibility Criteria
Inclusion
- Confirmed case of Covid-19 (by RT-PCR, HRCT)
- Admission to Intensive Care Unit
- Need for intubation and mechanical ventilation (PaO2/FiO2 \< 100-200)
- Written informed consent
Exclusion
- Pregnancy and breastfeeding
- History of G6PDH deficiency
- Preadmission anticoagulation
- Severe renal insufficiency (glomerular filtration rate \<30 mL/min/1.73m2)
- Medical records of cirrhosis
- Active chronic hepatitis
- Severe hepatic disease defined by GOT or GPT levels three times above the normal upper limit
- Patients with history of allergic reaction or significant sensitivity to Methylene blue
- Treatment with immunosuppressive agents
- Use of other investigational drugs in the moment of inclusion
Key Trial Info
Start Date :
April 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 21 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04370288
Start Date
April 19 2020
End Date
September 21 2020
Last Update
May 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imam Reza Hospital
Mashhad, Razavi Khorasan Province, Iran, 9137913316